mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis
Kidney transplant recipients are at high risk of developing severe COVID-19 due to the coexistence of several transplant-related comorbidities (e.g., cardiovascular disease, diabetes) and chronic immunosuppression. As a consequence, a large part of SARS-CoV-2 infected patients have been managed with...
Saved in:
Main Authors: | Simona Granata (Author), Pierluigi Carratù (Author), Giovanni Stallone (Author), Gianluigi Zaza (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oxidative Stress and Ischemia/Reperfusion Injury in Kidney Transplantation: Focus on Ferroptosis, Mitophagy and New Antioxidants
by: Simona Granata, et al.
Published: (2022) -
Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients
by: Antony Brayan Campos-Salazar, et al.
Published: (2018) -
Place of mTOR inhibitors in management of BKV infection after kidney transplantation
by: Thomas Jouve, et al.
Published: (2016) -
Gypenosides Attenuate Pulmonary Fibrosis by Inhibiting the AKT/mTOR/c-Myc Pathway
by: Suqing Liu, et al.
Published: (2022) -
Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
by: Mathis Wehming, et al.
Published: (2023)